Halozyme Therapeutics, Inc. announced that Roche’s Phase 3 OCARINA II trial evaluating OCREVUS® with ENHANZE® as a twice a year 10-minute subcutaneous injection, met its primary and secondary endpoints in patients with relapsing forms of multiple sclerosis or primary progressive MS.
